Cyclerion Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYCN research report →
Price Chart
About the company
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier.
- CEO
- Regina Graul
- IPO
- 2019
- Employees
- 1
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on CYCN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.05M
- P/E
- -2.37
- PEG
- 0.03
- P/S
- 10.03
- P/B
- 3.40
- EV/EBITDA
- -2.63
- Div Yield
- 0.00%
- Gross Margin
- 61.58%
- Op Margin
- -359.16%
- Net Margin
- -353.00%
- ROE
- -87.96%
- ROIC
- -134.15%
Latest fiscal year · YoY change
- Revenue
- $2.07M+3.7%
- Gross Profit
- $2.07M+3.7%
- Op Income
- $-4,973,000
- Net Income
- $-3,528,000-15.4%
- EPS
- $-1.09+9.9%
- OCF Growth
- +23.5%
- FCF Growth
- +23.5%
- 52W High
- $8.48
- 52W Low
- $1.03
- 50D MA
- $3.52
- 200D MA
- $2.40
- Beta
- 1.75
- RSI (14)
- 69
- Avg Volume
- 25.44K
No earnings-call transcripts are available for CYCN yet.
- Free Float
- 67.1%
- Shares Outstanding
- 4.68M
- Float Shares
- 3.14M
of shares held by institutions
19 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Tyndall Capital Partners L P | 155.19K | ▼ 9.59K |
| Two Sigma Advisers, LP | 28.30K | ▲ 28.30K |
| Vanguard Group Inc | 23.49K | 0 |
Held by 8 ETFs
Biggest fund positions in CYCN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 14, 26 | CHICKO RHONDA M. | other | 25,000 |
| Aug 14, 26 | CHICKO RHONDA M. | other | 25,000 |
| Aug 14, 26 | Graul Regina Margaret | other | 55,849 |
| Aug 14, 26 | Graul Regina Margaret | other | 48,629 |
| Aug 14, 26 | Graul Regina Margaret | other | 55,849 |
| Jul 16, 26 | Hecht Peter M | other | 351,037 |
| Jul 16, 26 | Hecht Peter M | other | 351,037 |
| Aug 7, 25 | CHICKO RHONDA M. | other | 25,000 |
| Mar 25, 25 | Hecht Peter M | other | 181,818 |
| Mar 25, 25 | Higgins Michael J | other | 9,090 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CYCN coverage
Recent articles, reports, and earnings notes.
No research on CYCN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CYCN report →Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?
prnewswire.com · Apr 9
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)
prnewswire.com · Apr 2
CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
businesswire.com · Apr 2
Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders
prnewswire.com · Apr 1
Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing
benzinga.com · Apr 1
Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript
seekingalpha.com · Apr 1
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
businesswire.com · Apr 1
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
globenewswire.com · Feb 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.